ArticleFrontiers in oncology2026
ZEB1 directly activates IL-6 to promote triple-negative breast cancer stemness in an epigenetically constrained context.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ZEB1 is a key driver of breast cancer pathogenesis and therapy resistance, largely through its ability to promote cancer stem cells (CSCs). Although tumor-secreted cytokines such as IL-6 are known to support tumor progression, how their expression is regulated by upstream transcriptional factors such as ZEB1 remains incompletely understood. Here, we identify IL-6 as a direct transcriptional target of ZEB1 and reveal an epigenetic dimension associated with this regulation. Mechanistically, ZEB1 binds to specific E2-box elements within the IL-6 promoter and activates its transcription. The IL-6 promoter exhibits local DNA methylation, and ZEB1-dependent IL-6 expression was further enhanced by DNA methyltransferase and histone deacetylase inhibitors, suggesting that the local epigenetic context constrains IL-6 transcription. ZEB1 overexpression was also accompanied by enrichment of the active histone marks H3K27ac and H3K4me3 at the IL-6 promoter, consistent with a more transcriptionally permissive local chromatin state. Functionally, the ZEB1-induced IL-6 expression enhanced CSC-associated properties
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.